For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

FY 2016 Funding Bill Falls Short in Fight Against Hepatitis B and C

May 15, 2016

FOR IMMEDIATE RELEASE

NVHR Applauds Modified Language to Support Syringe Services and VA Funding for HCV Treatment But Disappointed with Inadequate Funding Increase

WASHINGTON, D.C., Wednesday, December 16, 2015 – Congress today released the Fiscal Year (FY) 2016 Omnibus Appropriations Bill, which includes a $2.6 million increase ($34 million total) for the Division of Viral Hepatitis (DVH) at the Centers for Disease Control and Prevention (CDC) - the only agency dedicated to combating all five hepatidites (hepatitis B and C being most common), both domestically and globally. This funding level falls far short of the President’s recommended doubling of spending for DVH in his FY 2016 budget proposal and the $5 million increase recommended by the U.S. Senate earlier this year.

“While we appreciate any increase in funding for viral hepatitis services, Congress has missed an opportunity to demonstrate leadership in addressing a serious and growing epidemic that affects over 5 million Americans and is the leading cause of liver cancer in the country,” said Ryan Clary, Executive Director. “The inadequate funding in this spending bill will harm efforts to identify the majority of people with chronic hepatitis B and C who are not aware of their status and link them to lifesaving care and treatment.”

The spending bill does represent major progress on language allowing for more flexibility in the use of federal funds for syringe services programs – a critical component of comprehensive viral hepatitis prevention. “Syringe services programs are on the front lines of this epidemic, and the need for adequate funding to ensure comprehensive services, sustainability, and geographic coverage is essential. We are extremely gratified to see movement on the issue,” said Christine Rodriguez, Senior Policy Manager.

NVHR also strongly supports and appreciates language in the spending bill funding the treatment of hepatitis C in the VA system at no less than $1.5 billion in Fiscal Year 2016, which is $810 million above the President’s request. Our nation’s veterans are disproportionately impacted by hepatitis C and deserve swift access to curative hepatitis C treatment. This investment will result in avoiding future spending on liver transplants, treatment of liver cancer, and other health care costs.

With the World Health Organization setting hepatitis elimination goals for 2030, and the Institute of Medicine exploring a similar United States elimination strategy, it is imperative that Congress provide a meaningful increase in funding in the FY 2017 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. “Elimination of hepatitis B and C in the United States should be the goal,” said Clary. “NVHR will continue working with our partners to ensure that resources are available to significantly expand viral hepatitis prevention, screening, care, and treatment services.”

About National Viral Hepatitis Roundtable (NVHR)

The National Viral Hepatitis Roundtable is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance. Please visit us at nvhr.org.

###

Contact: Christine Rodriguez, National Viral Hepatitis Roundtable

703-945-9698

crodriguez@nvhr.org

nvhr.org

Metadata